Mr. Song Li has over 8 years of experience in antibody drug discovery and process development. He has much expertise in lead slection, antibody engineering and optimization, cell line and process development, and antibody characterization.
Between 2004 and 2008, Mr. Li studied at Inner Mongolia University of Science & Technology and obtained a Bachelor degree in Biological Sciences. Between 2008 and 2011, he studied at the College of Life Sciences of Jilin Agricultural University and obtained a Master degree in Biochemistry and Molecular Biology. Between 2009 and 2011, Mr. Li completed his graduation project at Beijing Chest Hospital and Capital Medical University. Between 2011 and 2012, he worked as a researcher at Shenzhen Yidakai Biotechnology Co., Ltd. and led molecular cloning and protein prokaryotic expression efforts. Between 2012 and 2015, Mr. Li worked as a manager at Huabo Biopharm (Shanghai) Co., Ltd., and led efforts in vitro characterization, cell line construction and molecular cloning.
Since 2015, he has been working as the R&D Director of Immuneonco, and is responsible for the research and development of the company's compound pipeline.